Markets:

Overview

News

Currencies

International

Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

0.6817 -0.0083 (-1.20%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Lexaria Discovers Potential Novel Mechanism From Hypertension Study Of Processed CBD ↗

February 21, 2023

Via Benzinga

This BioTech Company Using CBD For Enhanced Hypertension Treatment Could Be One To Watch ↗

November 07, 2022

Lexaria Bioscience Corp.

Via Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗

August 10, 2022

Via Benzinga

Lexaria Gets FDA's Positive Feedback On Pre-Clinical Trial Of Hypertension Candidate ↗

August 10, 2022

Lexaria Bioscience Corp. (NASDAQ: LEXX) announced that it has received a positive full written response from the Food and Drug Administration (FDA) from its pre-Investigational New Drug meeting...

Via Benzinga

Lexaria Bioscience' Tech Processed Cannabidiol Receives Positive FDA Feedback For Hypertension ↗

August 10, 2022

Via Benzinga

Recap of Wednesday's Biotech Catalysts - End of The Day Summary ↗

July 27, 2022

Via Benzinga

Lexaria Posied To Receive US Patent For DehydraTECH To Deliver Antiviral Drugs ↗

April 21, 2022

Via Benzinga

Why Is Lexaria Bioscience (LEXX) Stock Up Today? ↗

April 14, 2022

Today, investors in Lexaria Bioscience and LEXX stock are seeing impressive gains as investors price a key catalyst into shares.

Via InvestorPlace

Lexaria's DehydraTECH CBD Hypertension Study Dosing Complete With No Serious Adverse Events ↗

July 27, 2022

Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) revealed that dosing with Lexaria's DehydraTECH-processed CBD has been completed in its multi-week human clinical hypertension study HYPER-H21-4

Via Benzinga

67 Biggest Movers From Yesterday ↗

June 22, 2022

Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be taken private by TPG Capital.

Via Benzinga

Why Lexaria Shares Are Rising Today ↗

April 14, 2022

Via Benzinga

Nasdaq Rises 2.5%; ACADIA Pharmaceuticals Shares Plummet ↗

June 21, 2022

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 2.5% on Tuesday.

Via Benzinga

Why Shares Of Lexaria Biosciences Are Trading Higher ↗

June 21, 2022

Lexaria Bioscience Corp. (NASDAQ: LEXX) shares are trading higher after the company announced manufacturing and license agreements with BevNology.

Via Benzinga

Dow Jumps 550 Points; Convey Health Solutions Shares Spike Higher ↗

June 21, 2022

U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 550 points on Tuesday.

Via Benzinga

45 Stocks Moving In Tuesday's Mid-Day Session ↗

June 21, 2022

Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.8% to $10.31 as the company agreed to be taken private by TPG Capital,.

Via Benzinga

Lexaria Bioscience (NASDAQ: LEXX) Advancing DehydraTECH-Nicotine Research ↗

April 26, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria expects to begin dosing this summer as part of a human...

Via Benzinga

Lexaria Bioscience (NASDAQ: LEXX) Secures Patent For DehydraTECH To Deliver Antivirals ↗

April 22, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

53 Biggest Movers From Yesterday ↗

April 21, 2022

Gainers ION Geophysical Corporation (NYSE: IO) shares surged 91.2% to settle at $0.6980 on Wednesday. ION Geophysical was awarded a five-year contract by Brunei Shell Petroleum...

Via Benzinga

Lexaria Bioscience (NASDAQ: LEXX) Commences Its Most Comprehensive Study To Date ↗

April 20, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

28 Stocks Moving In Wednesday's Mid-Day Session ↗

April 20, 2022

Gainers Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) climbed 58.3% to $2.2950 after jumping around 22% on Tuesday. AlloVir, Inc. (NASDAQ: ALVR) shares climbed 39% to $7.52...

Via Benzinga

Lexaria Bioscience (NASDAQ: LEXX) Announces Positive Results From Hypertension Study ↗

April 18, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 14, 2022

Gainers

Via Benzinga

51 Biggest Movers From Thursday ↗

April 18, 2022

Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 69.4% to close at $2.44 on Thursday. Ally Bridge Group recently reported a purchase of 21.176 million shares of...

Via Benzinga

Lexaria Bioscience (NASDAQ: LEXX) Issues Update On Human Nicotine Study ↗

April 13, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Lexaria Bioscience (NASDAQ: LEXX) Begins Nicotine Formulation Creation, Evaluation Program ↗

April 12, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Lexaria Aims To Demonstrate DehydraTECH's Performance In Epilepsy Research ↗

April 11, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Lexaria Bioscience's 24th Patent Sets Stage For Market Opportunities In Australia ↗

March 31, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Lexaria Bioscience Optimistic About Upcoming Hypertension Study ↗

March 28, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Lexaria's IP Portfolio Grows Following Receipt Of 24th Granted Patent ↗

March 22, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria has received a new patent entitled “Compositions...

Via Benzinga

Lexaria Bioscience Commences DehydraTECH-CBD Epilepsy Research Program ↗

March 16, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

Headline News about Lexaria Bioscience Corp. - Common Stock

Starting at $3.75/week.

Subscribe Today